NEW YORK (GenomeWeb) – Cancer Genetics said after the close of the market on Monday that its fourth quarter revenues rose 4 percent year over year, falling short of the consensus Wall Street estimate.

For the three months ended Dec. 31, 2017, the firm posted $7.5 million in total revenues, up from $7.2 million a year ago. On average, Wall Street had expected $9.2 million in revenues.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.